336 related articles for article (PubMed ID: 37158690)
21. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
22. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer.
Harris RJ; Cheung A; Ng JCF; Laddach R; Chenoweth AM; Crescioli S; Fittall M; Dominguez-Rodriguez D; Roberts J; Levi D; Liu F; Alberts E; Quist J; Santaolalla A; Pinder SE; Gillett C; Hammar N; Irshad S; Van Hemelrijck M; Dunn-Walters DK; Fraternali F; Spicer JF; Lacy KE; Tsoka S; Grigoriadis A; Tutt ANJ; Karagiannis SN
Cancer Res; 2021 Aug; 81(16):4290-4304. PubMed ID: 34224371
[TBL] [Abstract][Full Text] [Related]
25. Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer.
Jiang K; Dong M; Li C; Sheng J
Front Oncol; 2021; 11():557477. PubMed ID: 33854958
[No Abstract] [Full Text] [Related]
26. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
27. High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer.
Liu X; Wu Y; Zhang Y; Bu D; Wu C; Lu S; Huang Z; Song Y; Zhao Y; Guo F; Ye P; Fu C; Shen L; Zhang J; Wang H; Duan X; Wu J
Front Oncol; 2021; 11():747300. PubMed ID: 34604090
[TBL] [Abstract][Full Text] [Related]
28. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
29. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
30. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
31. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
32. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
34. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
35. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
36. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.
Savas P; Virassamy B; Ye C; Salim A; Mintoff CP; Caramia F; Salgado R; Byrne DJ; Teo ZL; Dushyanthen S; Byrne A; Wein L; Luen SJ; Poliness C; Nightingale SS; Skandarajah AS; Gyorki DE; Thornton CM; Beavis PA; Fox SB; ; Darcy PK; Speed TP; Mackay LK; Neeson PJ; Loi S
Nat Med; 2018 Jul; 24(7):986-993. PubMed ID: 29942092
[TBL] [Abstract][Full Text] [Related]
37. Increased Tumour Infiltration of CD4+ and CD8+ T-Lymphocytes in Patients with Triple Negative Breast Cancer Suggests Susceptibility to Immune Therapy.
Sikandar B; Qureshi MA; Naseem S; Khan S; Mirza T
Asian Pac J Cancer Prev; 2017 Jul; 18(7):1827-1832. PubMed ID: 28749113
[TBL] [Abstract][Full Text] [Related]
38. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
[TBL] [Abstract][Full Text] [Related]
39. Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.
Malla RR; Vasudevaraju P; Vempati RK; Rakshmitha M; Merchant N; Nagaraju GP
Cancer; 2022 Mar; 128(6):1171-1183. PubMed ID: 34990009
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
